Research progress on CGRP/CGRPR targeted monoclonal antibody and its application in treatment of migraine
10.13200/j.cnki.cjb.004015
- VernacularTitle:CGRP/CGRPR靶向单克隆抗体及其在偏头痛治疗中的研究进展
- Author:
DU Jialiang
- Publication Type:Journal Article
- Keywords:
Calcitonin gene-related peptide(CGRP);
Monoclonal antibody;
Migraine
- From:
Chinese Journal of Biologicals
2025;38(06):758-763
- CountryChina
- Language:Chinese
-
Abstract:
With the deepening of the research on the mechanism of migraine,the role of calcitonin gene-related peptide(CGRP) in the trigeminal neurovascular system in the pathogenesis of migraine has attracted much attention,and has become the most promising target for the treatment and prevention of migraine. By 2020,four kinds of CGRP/CGRP receptor(CGRPR) targeted monoclonal antibody drugs have been approved by the Food and Drug Administration(FDA) and/or the European Medicines Agency(EMA). This paper reviewed the research progress of CGRP/CGRPR targeted monoclonal antibody in the treatment of migraine.
